IBT-B.ST
Infant Bacterial Therapeutics AB (publ) [IBT-B.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IBT-B.ST Stock Summary
In the News
IBT-B.ST Financial details
Company Rating
-
Market Cap
1.08B
Income
-123.07M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-11.54
Forward P/E
-
PEG
-1.62
P/S
-
P/B
4.06
P/C
-
P/FCF
-14.46
Quick Ratio
9.03
Current Ratio
9.26
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-9.92
EPS next Y
-
EPS next Q
-
EPS this Y
71.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
31.6%
-
-
-
-
SMA20
-3.39%
SMA50
54.05%
SMA100
23.91%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-38%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
41.3-106.5
52W High
-48.3%
52W Low
+33.66%
RSI
46
Rel Volume
1.5
Avg Volume
7.03K
Volume
10.58K
Perf Week
-5.03%
Perf Month
-11.47%
Perf Quarter
-
Perf Half Y
3.01%
-
-
-
-
Beta
1.01
-
-
Volatility
1.32%, 1.9%
Prev Close
-2.66%
Price
54.8
Change
-2.32%
Company Profile
- Volume Average 7.03K
- Market Capitalization 1.08B
- Employee 8
- CEO Mr. Staffan Stromberg Ph.D.
- Headquarters Stockholm,SE
- IPO Date 2016-03-29
-
Website
https://www.ibtherapeutics.com 
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
